U-47700

COPD, asthma, sleep apnea, pneumonia, restrictive lung disease

Pre-existing respiratory impairment represents an absolute contraindication. U-47700 produces dose-dependent respiratory depression via MOR activation in the pre-Bötzinger complex. Applied to a compromised respiratory system, even sub-heavy doses may produce fatal respiratory failure. All documented U-47700 fatalities involved respiratory depression as the terminal mechanism.

cirrhosis, acute hepatitis, severe hepatic insufficiency

Reduced hepatic CYP3A4 activity would decrease U-47700 clearance, effectively increasing the delivered dose. Given the compound's narrow therapeutic index, even moderate increases in plasma concentration could shift exposure into the lethal range. No U-47700-specific hepatic interaction data exist; this is inferred from its established CYP3A4-dependent metabolism (Krotulski et al. 2018).

pregnancy, breastfeeding

No U-47700-specific reproductive or teratogenicity data exist. The contraindication is inferred from the established risk of neonatal opioid withdrawal syndrome (NOWS) with all full MOR agonists. Given U-47700's high potency and short duration, the withdrawal cycling pattern could be particularly harmful to fetal development.

benzodiazepines, alcohol, GHB, GBL, barbiturates, other opioids, sedative-hypnotics

Co-administration with any CNS depressant is an absolute contraindication based on direct fatal case evidence. The majority of documented U-47700 fatalities involved polysubstance use with CNS depressants — designer benzodiazepines, alcohol, and other opioids are the dominant co-factors in fatal outcomes. The German 26-case series found 15/26 involved co-use of other NPS.

opioid-naive individuals

U-47700's narrow therapeutic index makes it exceptionally hazardous in opioid-naive individuals. The 10-fold range from threshold (1 mg) to heavy (10+ mg) is extremely compressed for an opioid. Opioid-naive users lack MOR desensitization that provides tolerance-mediated respiratory protection in experienced users. Fatal concentrations overlap with the upper end of recreational dosing.

ketoconazole, clarithromycin, ritonavir, itraconazole, grapefruit juice

Because U-47700 is metabolized primarily by CYP3A4, potent inhibitors of this enzyme could substantially increase plasma concentrations. Given the narrow therapeutic index, even moderate pharmacokinetic interaction could shift exposure into the lethal range. No published CYP interaction studies specific to U-47700 exist; the mechanism is inferred from established CYP3A4-dependent metabolism.